Patents by Inventor Roger Coleman
Roger Coleman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6479630Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel purinergic PU2 receptor (PNR) expressed in human placenta. The present invention also provides for antisense molecules to the nucleotide sequences which encode PNR, expression vectors for the production of purified PNR, antibodies capable of binding specifically to PNR, hybridization probes or oligonucleotides for the detection of PNR-encoding nucleotide sequences, genetically engineered host cells for the expression of PNR, and diagnostic tests based on PNR-encoding nucleic acid molecules or antibodies produced against the polypeptide PNR.Type: GrantFiled: June 22, 1998Date of Patent: November 12, 2002Assignee: Incyte GenomicsInventors: Roger Coleman, Janice Au-Young, Susan G. Stuart, Karl J. Guegler
-
Publication number: 20020164704Abstract: The present invention provides a polynucleotide which identifies and encodes a novel human monocyte chemotactic proprotein (MCPP). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding MCPP. The invention also provides for the use of substantially purified MCPP and its agonists, antibodies, antagonists or inhibitors in pharmaceutical compositions for treatment of diseases associated with expression of MCPP. Additionally, the invention provides for use of antisense molecules in pharmaceutical compositions for treatment of diseases associated with the expression of MCPP. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or transcripts of MCPP and anti-MCPP antibodies which specifically bind to MCPP.Type: ApplicationFiled: October 26, 2001Publication date: November 7, 2002Applicant: Incyte Pharmaceuticals, Inc.Inventors: Roger Coleman, Jennifer L. Hillman, Janice Au-Young
-
Patent number: 6475485Abstract: The present invention provides two novel human cathepsin proteins (HCPs) and polynucleotides encoding HCPs. The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding HCPs. The invention also provides for the production and use of antibodies to HCPs in pharmaceutical compositions for the treatment of disease processes that include cancers, inflammation, metastasis and peptide and proenzyme processing. In addition, the invention provides for the production and use of inhibitors of HSPs in pharmaceutical compositions for the treatment of diseases. The invention also describes diagnostic assays which utilize the polynucleotide to hybridize with the transcripts encoding HCPs. The invention also provides for the use of antisense molecules in pharmaceutical compositions as a therapeutics in cancers, inflammation, metastasis and peptide and proenzyme processing.Type: GrantFiled: August 31, 1999Date of Patent: November 5, 2002Assignee: Incyte Genomics, Inc.Inventors: Olga Bandman, Roger Coleman
-
Publication number: 20020155545Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode novel expressed chemokines (PANEC-1 and PANEC-2) from human pancreas cells. The present invention also provides for antisense molecules to the nucleotide sequences which encode PANEC-1 and PANEC-2, expression vectors for the production of purified PANEC-1 and PANEC-2, antibodies capable of binding specifically to PANEC-1 and PANEC-2, hybridization probes or oligonucleotides for the detection of PANEC-1- or PANEC-2- encoding nucleotide sequences, genetically engineered host cells for the expression of PANEC-1 and PANEC-2, diagnostic tests for chemokine activation based on PANEC-1- and PANEC-2- encoding nucleic acid molecules and antibodies capable of binding specifically to the protein.Type: ApplicationFiled: January 25, 2002Publication date: October 24, 2002Applicant: Incyte Pharmaceuticals, Inc.Inventors: Roger Coleman, Olga Bandman, Craig G. Wilde
-
Publication number: 20020146712Abstract: The invention provides a cDNA which encodes a tumor suppressor. It also provides for the use of the cDNA, protein, and antibody in the diagnosis, prognosis, treatment and evaluation of therapies for cancer. The invention further provides vectors and host cells for the production of the protein and transgenic model systems.Type: ApplicationFiled: August 7, 2001Publication date: October 10, 2002Inventors: Richard D. Goold, Ingrid E. Akerblom, Jeffrey J. Seilhamer, Roger Coleman
-
Publication number: 20020142398Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel expressed chemokine (FSEC) from human fetal spleen cells. The present invention also provides for antisense molecules to the nucleotide sequences which encode FSEC, expression vectors for the production of purified FSEC, antibodies capable of binding specifically to FSEC, hybridization probes or oligonucleotides for the detection of FSEC-encoding nucleotide sequences, genetically engineered host cells for the expression of FSEC, diagnostic tests for chemokine activation based on FSEC-encoding nucleic acid molecules and antibodies capable of binding specifically to the protein.Type: ApplicationFiled: May 29, 2002Publication date: October 3, 2002Applicant: Incyte Genomics, Inc.Inventors: Roger Coleman, Craig G. Wilde, Jeffrey J. Seilhamer
-
Publication number: 20020127648Abstract: The present invention provides a human C5a-like receptor (HCOR) and polynucleotides which identify and encode HCOR. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HCOR and a method for producing HCOR. The invention also provides agonists, antibodies, or antagonists specifically binding HCOR, and their use, in the prevention and treatment of diseases associated with expression of HCOR. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HCOR for the treatment of diseases associated with the expression of HCOR. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HCOR.Type: ApplicationFiled: December 18, 2001Publication date: September 12, 2002Applicant: Incyte Pharmaceuticals, Inc.Inventors: Roger Coleman, Olga Bandman
-
Publication number: 20020128443Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel thrombin receptor homolog (TRH) expressed in human liver. The present invention also provides for antisense molecules to the nucleotide sequences which encode TRH, diagnostic tests based on TRH encoding nucleic acid molecules, expression vectors for the production of purified TRH, antibodies capable of binding specifically to TRH, hybridization probes or oligonucleotides for the detection of TRH-encoding nucleotide sequences, genetically engineered host cells for the expression of TRH, and antagonists, antibodies and inhibitors with specific binding activity for the polypeptide TRH.Type: ApplicationFiled: November 28, 2001Publication date: September 12, 2002Applicant: Incyte Pharmaceuticals, Inc.Inventors: Roger Coleman, Janice Au-Young, Olga Bandman, Jeffrey J. Seilhamer
-
Publication number: 20020082387Abstract: The present invention provides a human proline-rich membrane protein (PRMP) and polynucleotides which identify and encode PRMP. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding PRMP and a method for producing PRMP. The invention also provides for agonists, antibodies, or antagonists specifically binding PRMP, and their use, in the prevention and treatment of diseases associated with expression of PRMP. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding PRMP for the treatment of diseases associated with the expression of PRMP. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding PRMP.Type: ApplicationFiled: July 18, 2001Publication date: June 27, 2002Applicant: Incyte Pharmaceuticals, Inc.Inventors: Janice Au-Young, Roger Coleman
-
Patent number: 6235880Abstract: The present invention provides a human sulfonylurea receptor (SURH) and the polynucleotides which identify and encode SURH. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding SURH and methods for producing the protein. The invention also provides pharmaceutical compositions containing SURH, agonists to SURH, or antagonists to SURH, and in the use of such compositions for the prevention or treatment of diseases associated with the expression of SURH. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding SURH for the treatment of diseases associated with the expression of SURH. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, to hybridize to the genomic sequence or transcripts of polynucleotides encoding SURH, or anti-SURH antibodies which specifically bind to SURH.Type: GrantFiled: December 9, 1998Date of Patent: May 22, 2001Assignee: Incyte Pharmaceuticals, Inc.Inventors: Janice Au-Young, Olga Bandman, Roger Coleman
-
Patent number: 6171815Abstract: The present invention provides a human sulfonylurea receptor (SURH) and the polynucleotides which identify and encode SURH. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding SURH and methods for producing the protein. The invention also provides pharmaceutical compositions containing SURH, agonists to SURH, or antagonists to SURH, and in the use of such compositions for the prevention or treatment of diseases associated with the expression of SURH. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding SURH for the treatment of diseases associated with the expression of SURH. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, to hybridize to the genomic sequence or transcripts of polynucleotides encoding SURH, or anti-SURH antibodies which specifically bind to SURH.Type: GrantFiled: October 2, 1996Date of Patent: January 9, 2001Assignee: Incyte Pharmaceuticals, Inc.Inventors: Janice Au-Young, Olga Bandman, Roger Coleman
-
Patent number: 6143870Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel thrombin receptor homolog (TRH) expressed in human liver. The present invention also provides for antisense molecules to the nucleotide sequences which encode TRH, diagnostic tests based on TRH encoding nucleic acid molecules, expression vectors for the production of purified TRH, antibodies capable of binding specifically to TRH, hybridization probes or oligonucleotides for the detection of TRH-encoding nucleotide sequences, genetically engineered host cells for the expression of TRH, and antagonists, antibodies and inhibitors with specific binding activity for the polypeptide TRH.Type: GrantFiled: December 21, 1998Date of Patent: November 7, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Roger Coleman, Janice Au-Young, Olga Bandman, Jeffrey J. Seilhamer
-
Patent number: 6090377Abstract: The present invention provides novel monocyte activating cytokine (MAC) and a polynucleotide encoding MAC. The invention also provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding MAC. The invention also provides for the production and use of substantially purified MAC in pharmaceutical compositions for the treatment of cancer and disease of the immune system. The invention also describes diagnostic assays which utilize the polynucleotide to hybridize with the transcripts encoding MAC and antibodies which specifically bind to MAC.Type: GrantFiled: July 28, 1998Date of Patent: July 18, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Roger Coleman, Janice Au-Young, Lynn E. Murry
-
Patent number: 6080548Abstract: The invention provides human cyclic nucleotide phosphodiesterases (PDE8) and polynucleotides which identify and encode PDE8. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of PDE8.Type: GrantFiled: February 23, 1999Date of Patent: June 27, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Janice Au-Young, Benjamin G. Cocks, Roger Coleman, Jeffrey J. Seilhamer, Douglas A. Fisher
-
Patent number: 6066488Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a new cathepsin C homolog (RCP) expressed in THP-1 cells. The present invention also provides for antisense molecules to the nucleotide sequences which encode RCP, expression vectors for the production of purified RCP, antibodies capable of binding specifically to RCP, hybridization probes or oligonucleotides for the detection of RCP-encoding nucleotide sequences, genetically engineered host cells for the expression of RCP, diagnostic tests for activation of monocyte/macrophages based on RCP-encoding nucleic acid molecules, and use of the protein to produce antibodies capable of binding specifically to the protein and use of the protein to screen for inhibitors.Type: GrantFiled: June 9, 1997Date of Patent: May 23, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Roger Coleman, Scott Michael Braxton, Jeffrey J. Seilhamer
-
Patent number: 6051697Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel chemokine (EEC) expressed in human eosinophil cells. The present invention also provides for antisense molecules to the nucleotide sequences which encode EEC, expression vectors for the production of purified EEC, antibodies capable of binding specifically to EEC, hybridization probes or oligonucleotides for the detection of EEC-encoding nucleotide sequences, genetically engineered host cells for the expression of EEC, diagnostic tests for chemokine activation based on EEC-encoding nucleic acid molecules and antibodies capable of binding specifically to the protein.Type: GrantFiled: July 10, 1998Date of Patent: April 18, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Roger Coleman, Susan G. Stuart
-
Patent number: 6019966Abstract: The present invention provides a polynucleotide (hjak2) which identifies and encodes a novel human Jak2 kinase (HJAK2) which was expressed in the placenta. The present invention also provides for antisense molecules and oligomers designed from the nucleotide sequence or its antisense. The invention further provides genetically engineered expression vectors and host cells for the production of purified HJAK2 peptide, antibodies capable of binding to HJAK2, inhibitors which bind to HJAK2 and pharmaceutical compositions based on HJAK2 specific antibodies or inhibitors. The invention specifically provides for diagnostic assays based on altered hjak2 expression and which allow identification of such a condition. These assays utilize probes which comprise oligomers, fragments, or portions of hjak2 or its regulatory elements or antibodies specifically binding HJAK2.Type: GrantFiled: November 19, 1998Date of Patent: February 1, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Roger Coleman, Susan G. Stuart
-
Patent number: 6008039Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel purinergic P.sub.U2 receptor (PNR) expressed in human placenta. The present invention also provides for antisense molecules to the nucleotide sequences which encode PNR, expression vectors for the production of purified PNR, antibodies capable of binding specifically to PNR, hybridization probes or oligonucleotides for the detection of PNR-encoding nucleotide sequences, genetically engineered host cells for the expression of PNR, and diagnostic tests based on PNR-encoding nucleic acid molecules or antibodies produced against the polypeptide PNR.Type: GrantFiled: June 2, 1995Date of Patent: December 28, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Roger Coleman, Janice Au-Young, Susan G. Stuart, Karl J. Guegler
-
Patent number: 5998165Abstract: The present invention provides polynucleotides and related reagents which are associated with pancreatic and other cancers. These polynucleotides are designated PANC1A.Type: GrantFiled: March 15, 1996Date of Patent: December 7, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Richard D. Goold, Ingrid E. Akerblom, Jeffrey J. Seilhamer, Roger Coleman
-
Patent number: 5965129Abstract: The present invention provides two novel human cathepsin proteins (HCPs) and polynucleotides encoding HCPs. The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding HCPs. The invention also provides for the production and use of antibodies to HCPs in pharmaceutical compositions for the treatment of disease processes that include cancers, inflammation, metastasis and peptide and proenzyme processing. In addition, the invention provides for the production and use of inhibitors of HSPs in pharmaceutical compositions for the treatment of diseases. The invention also describes diagnostic assays which utilize the polynucleotide to hybridize with the transcripts encoding HCPs. The invention also provides for the use of antisense molecules in pharmaceutical compositions as therapeutics in cancers, inflammation, metastasis and peptide and proenzyme processing.Type: GrantFiled: May 18, 1998Date of Patent: October 12, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Roger Coleman